Does the lack of long-term data influence your consideration of utilizing zanubrutinib and venetoclax 1L in High-Risk CLL?

Not really. The CLL17 data showed essentially equivalent 3yr PFS between ibrutinib + venetoclax, ibrutinib monotherapy, and venetoclax + obinutuzumab. But even before those data were published, with the solid 36-month PFS data for zanubrutinib + venetoclax, it seemed clear that many of these patient...

Ideally, we would have longer-term data, but given the responses and adverse event profile we have seen in SEQUOIA Arm D, I'm comfortable using the combination. It is important to point out that patients in Arm D could continue zanubrutinib after completing venetoclax, and the majority of patients d...

Having long-term data on patients with TP53 aberrant CLL is very important. However, I do not think it would influence my decision to choose zanubrutinib + venetoclax in TP53-aberrant CLL. The reason is that data from the CAPTIVATE study showed that 1 year of treatment with ibrutinib + venetoclax le...